TROG 01.04
Trans-Tasman Radiation Oncology Group
•
326 patients. T3N0-2 on MRI or US.
•
Randomisation
–
SCRT 25/5 + early surgery + 6# chemo.
–
LCRT 50.4/28 + 5-FU + delayed surgery + 4# chemo
Ngan SY. J Clin Oncol. 2012;30(31):3827-33
SCRT LCRT
p value
3-year LR
7.5% 4.4% 0.23
Distal tumours (≤5 cm)
6/48
1/31
0.21
5-year OS
74% 70% 0.62
Late toxicity
5.8% 8.2% 0.53